IR vs PPCB · P/E 49, rev $7.24B vs P/E 0.0, $3.9M cap
Ingersoll Rand Inc (IR) versus Propanc Biopharma, Inc. Common Stock (PPCB) — a side-by-side from cached financials, not a winner call.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Propanc Biopharma, Inc. Common Stock (PPCB) is a biotechnology company listed on NASDAQ.
Latest reported IR revenue for 2024-12-31 was $7.24B. Net income was $846.3M. Revenue was up 5.2% from 2023-12-31 to 2024-12-31. IR currently screens at market cap $28.27B and trailing P/E 48.8.
PPCB does not have a complete income-statement cache yet.
IR currently screens at market cap $28.27B and trailing P/E 48.8. PPCB currently screens at market cap $3.9M and trailing P/E 0.0.
Not investment advice. Open the IR and PPCB stock pages for the full models.
Not investment advice.